Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TLR4 | O00206 | 8/20 | 0.47 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22431121 | 1.00 | PYGB (0.51) | PYGBMAPK1TLR4LY96TRPV1 | |
| SCHEMBL22431203 | 0.90 | PYGB (0.46) | PYGBMAPK1TLR4LY96GAA | |
| SCHEMBL21137865 | 0.89 | PYGB (0.64) | PYGBMAPK1GAA | |
| SCHEMBL18391212 | 0.89 | PYGB (0.64) | PYGBMAPK1GAA | |
| SCHEMBL22431287 | 0.88 | PYGB (0.44) | PYGBMAPK1TLR4LY96GAA | |
| SCHEMBL13321928 | 0.88 | PYGB (0.52) | PYGBMAPK1TLR4LY96TRPV1 | |
| SCHEMBL15504507 | 0.88 | PYGB (0.52) | PYGBMAPK1TLR4LY96TRPV1 | |
| SCHEMBL806360 | 0.88 | PYGB (0.52) | PYGBMAPK1TLR4LY96TRPV1 | |
| SCHEMBL10602999 | 0.88 | PYGB (0.52) | PYGBMAPK1TLR4LY96TRPV1 | |
| SCHEMBL31472776 | 0.88 | PYGB (0.52) | PYGBMAPK1TLR4LY96TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291071-A1 | GLYCOPEPTIDE COMPOUNDS, METHODS FOR PRODUCING THE SAME, AND USES THEREOF | ACADEMIA SINICA (TW) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291071-A1 | GLYCOPEPTIDE COMPOUNDS, METHODS FOR PRODUCING THE SAME, AND USES THEREOF | B3GAT3, MGAM, GALNT14 | PYGB 529/4885MAPK1 3577/4885TLR4 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.